Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, PepsiMan, Top Penny, kyallen, beer$$money, xlogit3k
Search This Board: 
Last Post: 3/23/2018 10:35:00 PM - Followers: 378 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,

Facts About Hodgkins Lymphoma

Description of Hodgkins Lymphoma. Hodgkins Lymphoma is a cancer of the lymphatic system. Malignant Reed Sternberg cells invade and destroy the architecture of the lymph nodes and infiltrate major organs such as the liver and spleen in more advanced cases (Stages III and IV). Treatment options for Hodgkins Lymphoma are chemotherapy, radiotherapy or chemotherapy plus radiotherapy. More difficult cases may require high dose chemotherapy and stem cell transplant. In addition to the stage of the disease other factors such as age, general health and location of the disease are considered important in treatment decisions. In recent years PET/CT scans have been helpful in determining the extent of Hodgkins disease and assessing how well treatment is working. In some patients Hodgkins may never go away completely and regular treatments are required to control the disease while others experience relapses. Nowadays chemotherapy plus radiotherapy to involved areas is considered as standard treatment for patients with early stage Hodgkins Lymphoma (Stages I and II) and the incidence of survival in the U.S. after 5-years is about 90%. The 5-year survival rate for stage III patients is about 80% while it is 65% for stage IV patients. Due to long term adverse effects such as secondary malignancies causing both morbidity and mortality, the role of radiotherapy has been questioned and other means of treatment are being sought.

Incidence of Hodgkins Lymphoma. This disease is a cancer that is found most frequently in two different age groups (15 to 35 and over 55) and occurs in both sexes although more common in males and individuals with HIV, and in the third decade of life.. The overall incidence of Hodgkins Lymphoma is 2.7 per 100,000 persons and in the U.S. 185,793 individuals were stricken with this disease in 2011. The worldwide estimate for treatment of Hodgkins Lymphoma is estimated to be $1 to 2 billion. The cause of Hodgkins Lymphoma is unknown but factors such as smoking and alcohol have been linked to this disease, and siblings of with parents with Hodgkins have an increased risk (2 to 5X) of developing this disease. The specific factors triggering the conversion of normal lymphocytes to Hodgkins Lymphoma cells is unknown.

Facts about AML

Acute Myelocytic Leukemia (AML)

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is the most common acute leukemia type that affects adults. Other names for AML that refer to the same disease are acute myeloid leukemia and acute myeloblastic leukemia. AML is sometimes referred to as acute myelo cancer, acute myelo leukemia and acute myeloid cancer.

What is Acute Myelocytic Leukemia (AML)?

AML is an aggressive form of cancer of the blood and the bone marrow, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal white blood cells. The myeloid blood stem cells of the bone marrow develop into abnormal, poorly formed myeloblasts and do not become healthy white blood cells.
The incidence of myeloblastic leukemia in the USA is of about 1 case in 100 000 persons per year during the first 20 years of life, with a later increase to around 20 cases in 100 000 persons per year for octogenarians. Myeloid leukemia progresses rapidly and can typically be fatal within weeks or months.

Acute Myelocytic Leukemia (AML) Symptoms

Most signs and symptoms of AML are caused by the decreased ability of the body to fight off infection due to the replacement of normal blood cells with leukemic cells.
The symptoms of myelogenous leukemia are generally vague and non-specific. All or some of the following symptoms may be experienced by the person affected:

• Lethargy, chronic fatigue
• Fever (usually of unknown origin)
• Shortness of breath
• Inexplicable weight loss
• Frequent infections
• Headaches
• Pale skin, skin rash
• Non-specific bone pain
• Easy bruising
• Unusual bleeding such as nose or gum bleeding
• Blood in urine or stools
• Enlarged lymph nodes and/or spleen
• Abdominal fullness

Other symptoms of myelo leukemia include anemia, tumors of leukemic cells in the lung, breast, brain, uterus, ovary, stomach or prostate.

RCHA Recent News

Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials

June 21, 2017

Dr. Numbenjapon specializes in medical oncology, hematology, and stem cell transplantation. He has over 14 years of experience in Hematology and Oncology.

“We are confident that Dr. Numbenjapon is the best and most qualified physician to head our research abroad, and look forward to his guidance as we embark on the next phase of our clinical studies,” said Ben Chang, CEO.

Now that Rich Pharmaceuticals has filed an IND ( with the FDA and re- ceived approval to start phase I/II (, operations have progressed to the site level at Phramongkutklao Hospital and a full package has been submitted to the hospitals IRB (Review Board). "Rich Pharmaceuticals is pleased to have reached such a milestone and we look forward to patient enrollment at Phramongkutklao Hospital with the help of Dr. Numbenjapon," stated Mr. Chang.

Rich Pharmaceuticals Announces Institutional Review Board Submission

June 8, 2017

Beverly Hills, California - Rich Pharmaceuticals, Inc. (OTCPK: RCHA) (“Rich” or the “Company”), a bio- pharmaceutical Company focused on developing and commercializing innovative therapies in oncology an- nounced today that has filed its submission package to the Institutional Review Board (IRB) of Phramongkutklao Hospital in Bangkok, Thailand.

The submission is part of a process that leads to a study for the treatment of Acute Myelocytic Leukemia (AML) in refractory patients in a Phase I/II trial. “We are happy we’ve reached this milestone and we look forward to communicating further developments on this effort and other clinical milestones over time,” said Ben Chang, CEO.

The Company IRB submission was completed on May 31, 2017. An IRB is a group that is formally desig- nated to review and monitor biomedical research involving human patients. This submission is an integral to the Clinical Trial and drug approval process. 

Rich Pharmaceuticals Announces Clinical Site in Thailand

May 31, 2017

Beverly Hills, California - Rich Pharmaceuticals, Inc. (OTCPK: RCHA) (“Rich” or the “Company”), a bio- pharmaceutical company focused on developing and commercializing innovative therapies in oncology an- nounced today that it has selected a site and obtained investigator’s interest at Phramongkutklao Hospital in Bangkok, Thailand. Rich has engaged CMIC ASIA-PACIFIC, PTE. LTD. (“CMIC”) to assist in this project and they have already completed a site selection visit at Phramongkutklao Hospital, and the site has been cleared.

Rich and CMIC are preparing submission packages for the Hospital’s Internal Review Board (IRB) and the Thailand Food and Drug Administration (FDA). This package is near completion and the Company plans to submit it shortly. “The Company has purchased product liability insurance, the package is near completion and we hope to submit in the coming days,” said Ben Chang, CEO.

In cooperation with the Hospital, Rich is seeking to conduct a study for the treatment of Acute Myelocytic Leukemia (AML) in refractory patients in a Phase I/II trial. Acute Myelocytic Leukemia is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Because the incidence increases with age, it is expected that incidence will rise as population rises. 


Our Science

Rich Pharmaceuticals currently is focused on the clinical development of the chemical molecule TPA (12-O-tetradecanoylphorbol-13-acetate) for the treatment of acute myelogenous leukemia (AML). The Company has technical evidence to suggest that it may also be useful to treat other important diseases resulting in it being a widely used drug with major market potential.


TPA is a naturally occurring molecule that is isolated and purified from croton oil which is obtained from the seeds of Croton tiglium, a leafy shrub native to Southeast Asia. While this has been the major source of TPA for clinical studies conducted by Rich Company scientists recently devised a synthetic route for preparation of the drug which will ensure providing the necessary supply of highly pure drug for clinical use. TPA has characteristics that are unique to this chemical class including a potent ability to accelerate differentiation of the myeloid cell lines, HL-60 and THP-1, as well as mononuclear phagocytes from bone marrow and peripheral blood. The best characterized receptor for TPA is protein kinase C (PKC) which, once activated, induces substrate phosphorylation that propagates signals to the MAPK cascades. The effects of TPA on MAPK pathways may be particularly relevant to the differentiating and pro-apoptotic effects of TPA in certain cells. The capacity of TPA to activate PKC and to induce phenotypic changes characteristic of differentiation and/or apoptosis led investigators to study its effect in AML.

What Justifies the Use of TPA to Treat AML?

Acute myelogenous leukemia (AML) is an aggressive disease that requires urgent and intensive therapy. Patients diagnosed with AML are, on average, between 64 and 68 years of age. Patients over 60 treated with standard chemotherapy are cured of their disease less that 20 percent of the time. In addition, patients who develop AML after an antecedent hematologic disorder or prior leukemogenic chemotherapy/radiation have similarly poor outcomes as do patients whose disease is associated with specific cytogenetic and clinical features. Most patients diagnosed with AML have a poor prognosis. For patients with relapsed disease, no standard non-transplant therapy has demonstrated the capacity for cure and AML is often fatal.

In view of the above facts, it is obvious that new approaches to therapy are needed. The clinical studies completed and those currently in progress with TPA report feasibility and potential efficacy of this drug in patients with relapsed/refractory myeloid malignancies.

WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares

Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003



Chart View

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
News News Alert: Current Report Filing (8-k) 03/23/2018 05:23:44 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#25086  Sticky Note THUNDER BRINGS THE NEWS BusinessWire, GlobeNewswire and PR Newswire THEREISTHETHUNDER 03/14/18 09:55:22 AM
#20256  Sticky Note RCHA FDA Approval News & Must See Videos… stervc 09/29/17 02:54:06 PM
#25474   No Problem lojack! beer$$money 03/23/18 10:35:00 PM
#25473   Thanks! lojack 03/23/18 10:33:30 PM
#25472 Its posted here on this beer$$money 03/23/18 10:29:57 PM
#25471   Can you provide a link please? lojack 03/23/18 10:25:32 PM
#25470   There you go even better ;-) PepsiMan 03/23/18 10:05:35 PM
#25469   .004 to .0002... wow looks ugggggly! Time to whatarush12 03/23/18 09:04:06 PM
#25468   Not crazy that the Company only receiving .0001/share, stoprun 03/23/18 08:21:30 PM
#25467   You're right it's not bad but horrible since Axeman 03/23/18 08:14:10 PM
#25466   That’s not bad. Samsleiman 03/23/18 07:52:29 PM
#25465   Another 232,000,000 shares issued, March 7th thru March stoprun 03/23/18 07:43:10 PM
#25464   To .0007 actually. ;) Discipline15 03/23/18 07:13:58 PM
#25463   Does this mean more dilution on the way pantalons 03/23/18 06:41:07 PM
#25462   Good news I hope? Samsleiman 03/23/18 05:54:37 PM
#25461   Have a great weekend! Hoping to see some AKsquared 03/23/18 05:44:53 PM
#25460   Thanks AK beer$$money 03/23/18 05:43:44 PM
#25459   8-K out... AKsquared 03/23/18 05:43:07 PM
#25458   RCHA 19,788,265 T-Trade Buy @ .000295 beer$$money 03/23/18 04:28:59 PM
#25457   $RCHA .0002(364M ) x .0003(1M) and only 36M @.0004 SteevoTrader 03/23/18 04:15:54 PM
#25456   !!!!!!!!..Feed me..!!!!!!! lojack 03/23/18 04:13:55 PM
#25455   RCHA 364 milly on the 2?? beer$$money 03/23/18 03:59:29 PM
#25454   Absolutely. Last 9 months have made a PepsiMan 03/23/18 03:53:21 PM
#25453   $RCHA .0003 adding!! had many huge moves this SteevoTrader 03/23/18 03:50:47 PM
#25452   Absolutely. GO $RCHA PepsiMan 03/23/18 03:22:23 PM
#25451   Agreed! This is a “solid” Pharma play! Enough said..... beer$$money 03/23/18 03:21:04 PM
#25450   I usually do not divulge my stakes in lojack 03/23/18 03:16:50 PM
#25449   We can agree on the BEER part. PepsiMan 03/23/18 02:11:01 PM
#25448   Actually no it is not vague. It PepsiMan 03/23/18 02:09:14 PM
#25447   Good One Scott. TALK with ya later. I'm beer$$money 03/23/18 02:02:09 PM
#25446   Yep, that is something we can definitely agree Scott12 03/23/18 01:58:01 PM
#25445   That excerpt is about as vague as it Scott12 03/23/18 01:55:07 PM
#25444   As always, treat'em as a trade. On this beer$$money 03/23/18 01:53:11 PM
#25443   RCHA Any of you traders out there think beer$$money 03/23/18 01:48:19 PM
#25442   I'm glad to hear you are making some Scott12 03/23/18 01:45:00 PM
#25441   Your'e getting "Desperate", are you not????? YIPES!!!!YIPES!!!!!!! stoprun 03/23/18 01:43:58 PM
#25440   This is another great example at the vagueness Scott12 03/23/18 01:40:41 PM
#25439   Love it and how true. Glad to PepsiMan 03/23/18 01:40:40 PM
#25438   Incorrect. Fluff news would be to say PepsiMan 03/23/18 01:39:03 PM
#25437   RCHA Pepsi not the only trader who has beer$$money 03/23/18 01:38:26 PM
#25436   Bingo. Just reason it through (with a PepsiMan 03/23/18 01:36:22 PM
#25435   IMO, just more fluff news in order to Scott12 03/23/18 01:35:25 PM
#25434   Lol. “Educate “ someone else... I am busy lojack 03/23/18 01:34:44 PM
#25433   The stock was not primed to run but PepsiMan 03/23/18 01:33:43 PM
#25432   Sounds like looking for insider information I just PepsiMan 03/23/18 01:29:30 PM
#25431   Yeah and guess what happened to the pps Scott12 03/23/18 01:28:56 PM
#25430   Ok, Why does RCHA need Product Liability Insurance? beer$$money 03/23/18 01:26:39 PM
#25429   I'm glad to hear you have made $ Scott12 03/23/18 01:19:33 PM
#25428   Come on now Scott. You know also PepsiMan 03/23/18 01:13:05 PM
#25427   Either way.. Substantial news will be out to lojack 03/23/18 01:12:20 PM
#25426   I agree! I am trying to get this lojack 03/23/18 01:08:06 PM
#25425   I said about a year ago without having PepsiMan 03/23/18 01:07:22 PM